氘可来昔替尼能根治类风湿病吗？

Deucravacitinib can relieve symptoms such as joint pain caused by rheumatoid disease, but it cannot cure rheumatoid disease. Rheumatoid patients can undergo systemic treatment under the guidance of a doctor.

Drug introduction

Deucravacitinib (SOTYKTU™) is the first highly selective oral tyrosine kinase 2 (TYK2) inhibitor. It acts through an allosteric mechanism, binding to the catalytically inactive pseudokinase regulatory domain of TYK2 and stabilizing the inhibitory interaction between the regulatory and catalytic domains. Deucravacitinib was developed by Bristol-Myers Squibb to treat a variety of immune-mediated diseases, including psoriasis, psoriatic arthritis, lupus and inflammatory bowel disease.

The drug was first approved in the United States on September 9, 2022, for the treatment of adult patients with moderate to severe plaque psoriasis who are suitable for systemic therapy or phototherapy. On September 26, 2022, it was approved in Japan for the treatment of plaque psoriasis, generalized pustular psoriasis, and erythrodermic psoriasis.

Deuterated coxitinib does not cure rheumatoid disease

Deuterated colexitinib can be used to treat moderate to severe rheumatoid arthritis. By inhibiting certain special signaling pathways, it weakens the body's immune response and relieves symptoms. It can improve morning stiffness, joint pain, joint deformity, mobility impairment and other symptoms caused by rheumatoid arthritis, and reduce the impact of rheumatoid on patients' lives, but it cannot cure rheumatoid disease.

Deuterated colexitinib for the treatment of psoriasis

Deucravacitinib is an oral small molecule that works by allosterically inhibiting TYK2, increasing the drug's specificity for TYK2 but not other members of this kinase family. In clinical trials, Deucravacitinib has significant efficacy in the treatment of moderate to severe plaque psoriasis.

One study evaluated the safety and efficacy of the tyrosine kinase 2 (TYK2) inhibitor deucravacitinib in the treatment of moderate to severe plaque psoriasis. Study Selection and Data Extraction: Deucravacitinib demonstrated clinical efficacy in all Phase II and III clinical trials. After excluding long-term extension studies, there were a total of 2,248 patients in all studies, of whom 63.2% received deucravacitinib 6 mg daily. Among these subjects, the average proportion achieving PASI 75 (more than 75% reduction in Psoriasis Area and Severity Index) at 16 weeks was 65.1%. Compared with oral apremilast 30 mg twice daily, a higher proportion of patients treated with deucravacitinib 6 mg once daily achieved PASI 75 remission and a static physician global assessment score of 0 or 1.

The safety profile of deucravacitinib included mild (ae), most commonly nasopharyngitis. Relevance to Patient Treatment and Clinical Practice Compared with Existing Agents: While many existing treatments for moderate to severe plaque psoriasis rely on injectable dosage forms or extensive monitoring, deucravacitinib has the potential to reduce drug-related burden for patients.

Conclusion: Deucravacitinib, the first oral TYK2 inhibitor approved for adult patients with moderate to severe plaque psoriasis who are suitable for systemic therapy or phototherapy, demonstrated consistent efficacy and safety.

Recommended related articles: